Yarbrough Capital LLC Boosts Holdings in Zoetis Inc. (NYSE:ZTS)

Yarbrough Capital LLC raised its position in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 83.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,267 shares of the company’s stock after purchasing an additional 1,945 shares during the quarter. Yarbrough Capital LLC’s holdings in Zoetis were worth $735,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its holdings in Zoetis by 11.5% during the second quarter. Pacer Advisors Inc. now owns 38,279 shares of the company’s stock valued at $6,592,000 after purchasing an additional 3,945 shares in the last quarter. Keel Point LLC raised its position in shares of Zoetis by 10.1% during the second quarter. Keel Point LLC now owns 2,083 shares of the company’s stock valued at $359,000 after buying an additional 191 shares during the last quarter. Roberts Wealth Advisors LLC raised its position in shares of Zoetis by 6.0% during the second quarter. Roberts Wealth Advisors LLC now owns 22,804 shares of the company’s stock valued at $3,927,000 after buying an additional 1,297 shares during the last quarter. Valicenti Advisory Services Inc. raised its position in shares of Zoetis by 0.6% during the second quarter. Valicenti Advisory Services Inc. now owns 27,821 shares of the company’s stock valued at $4,791,000 after buying an additional 174 shares during the last quarter. Finally, Bath Savings Trust Co raised its position in shares of Zoetis by 8.8% during the second quarter. Bath Savings Trust Co now owns 17,438 shares of the company’s stock valued at $3,003,000 after buying an additional 1,414 shares during the last quarter. Hedge funds and other institutional investors own 89.47% of the company’s stock.

Insider Activity at Zoetis

In other Zoetis news, CEO Kristin C. Peck sold 13,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $179.97, for a total transaction of $2,339,610.00. Following the completion of the transaction, the chief executive officer now directly owns 56,843 shares of the company’s stock, valued at approximately $10,230,034.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Robert J. Polzer sold 1,179 shares of Zoetis stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $189.94, for a total transaction of $223,939.26. Following the completion of the transaction, the executive vice president now directly owns 2,353 shares of the company’s stock, valued at approximately $446,928.82. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Kristin C. Peck sold 13,000 shares of Zoetis stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $179.97, for a total transaction of $2,339,610.00. Following the transaction, the chief executive officer now directly owns 56,843 shares of the company’s stock, valued at $10,230,034.71. The disclosure for this sale can be found here. Insiders sold 25,930 shares of company stock valued at $4,691,799 in the last three months. 0.15% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ZTS has been the topic of several recent analyst reports. Piper Sandler lifted their price objective on shares of Zoetis from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Monday, August 14th. Stifel Nicolaus reiterated a “buy” rating and set a $205.00 price objective on shares of Zoetis in a research report on Tuesday, September 12th. StockNews.com upgraded shares of Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 14th. The Goldman Sachs Group boosted their price objective on shares of Zoetis from $204.00 to $213.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, Argus boosted their price objective on shares of Zoetis from $190.00 to $201.00 in a research report on Tuesday. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average price target of $222.44.

Read Our Latest Stock Analysis on Zoetis

Zoetis Stock Down 0.1 %

NYSE:ZTS traded down $0.25 during mid-day trading on Tuesday, reaching $179.40. The company’s stock had a trading volume of 295,047 shares, compared to its average volume of 1,972,554. The firm has a market capitalization of $82.58 billion, a PE ratio of 37.88, a price-to-earnings-growth ratio of 2.90 and a beta of 0.78. The company has a quick ratio of 1.97, a current ratio of 3.50 and a debt-to-equity ratio of 1.42. The stock has a fifty day moving average of $183.65 and a 200-day moving average of $175.28. Zoetis Inc. has a 1 year low of $124.15 and a 1 year high of $194.99.

Zoetis (NYSE:ZTSGet Free Report) last announced its earnings results on Tuesday, August 8th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.10. The business had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.16 billion. Zoetis had a net margin of 26.92% and a return on equity of 52.02%. The firm’s revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.20 earnings per share. Equities research analysts forecast that Zoetis Inc. will post 5.42 earnings per share for the current year.

About Zoetis

(Free Report)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read More

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.